{"entity":{"id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Immatics US, Inc., now recruiting.","summary":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT03686124 by Immatics US, Inc., with 375 participants planned, started 2019-05-14 and due to reach its primary completion in 2028-12. Interventions recorded: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab and IMADetect®.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03686124","url":"https://clinicaltrials.gov/study/NCT03686124"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["immatics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03686124","phase":"1/2","setting":"Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors","sponsor":"Immatics US, Inc.","enrolled":375,"outcomes":[]},"route":"/trials/nct03686124/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/"}]}}